Skip to Main Content
Contribute Try STAT+ Today

Amid ongoing concern over clinical trial disclosure, a new analysis finds that drug makers are doing a better job of making data available compared with the last spot check two years ago, although there is still room for improvement.

In reaching this conclusion, the researchers examined 505 trials for 19 novel new drugs that were approved in 2014 by the Food and Drug Administration and that were sponsored by 11 large drug makers. They found the public availability of results for each drug increased. The median disclosure rate of trials conducted in patients, for each drug, went up from a median fo 87 percent to 96 percent, when measured 13 months after approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.